351 related articles for article (PubMed ID: 19038046)
1. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Dineen SP; Sullivan LA; Beck AW; Miller AF; Carbon JG; Mamluk R; Wong H; Brekken RA
BMC Cancer; 2008 Nov; 8():352. PubMed ID: 19038046
[TBL] [Abstract][Full Text] [Related]
2. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Baker CH; Solorzano CC; Fidler IJ
Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Solorzano CC; Baker CH; Bruns CJ; Killion JJ; Ellis LM; Wood J; Fidler IJ
Cancer Biother Radiopharm; 2001 Oct; 16(5):359-70. PubMed ID: 11776753
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Conrad C; Ischenko I; Köhl G; Wiegand U; Guba M; Yezhelyev M; Ryan AJ; Barge A; Geissler EK; Wedge SR; Jauch KW; Bruns CJ
Anticancer Drugs; 2007 Jun; 18(5):569-79. PubMed ID: 17414626
[TBL] [Abstract][Full Text] [Related]
5. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R
Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
[TBL] [Abstract][Full Text] [Related]
9. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
Zhou S; Yang Y; Yang Y; Tao H; Li D; Zhang J; Jiang G; Fang J
PLoS One; 2013; 8(7):e68589. PubMed ID: 23874680
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
Lang SA; Schachtschneider P; Moser C; Mori A; Hackl C; Gaumann A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O
Mol Cancer Ther; 2008 Nov; 7(11):3509-18. PubMed ID: 19001434
[TBL] [Abstract][Full Text] [Related]
12. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Abdelrahim M; Baker CH; Abbruzzese JL; Safe S
J Natl Cancer Inst; 2006 Jun; 98(12):855-68. PubMed ID: 16788159
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Zhang X; Galardi E; Duquette M; Lawler J; Parangi S
Clin Cancer Res; 2005 Aug; 11(15):5622-30. PubMed ID: 16061881
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
15. VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model.
Shi Y; Tong M; Wu Y; Yang Z; Hoffman RM; Zhang Y; Tian Y; Qi M; Lin Y; Liu Y; Dai L; Sun Y; Wang Z
Anticancer Res; 2013 Feb; 33(2):409-17. PubMed ID: 23393331
[TBL] [Abstract][Full Text] [Related]
16. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Yapp DT; Wong MQ; Kyle AH; Valdez SM; Tso J; Yung A; Kozlowski P; Owen DA; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Ng SS
Angiogenesis; 2016 Apr; 19(2):229-44. PubMed ID: 26961182
[TBL] [Abstract][Full Text] [Related]
17. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
[TBL] [Abstract][Full Text] [Related]
18. Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
Amoh Y; Li L; Tsuji K; Moossa AR; Katsuoka K; Hoffman RM; Bouvet M
J Surg Res; 2006 May; 132(2):164-9. PubMed ID: 16500746
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Casneuf VF; Demetter P; Boterberg T; Delrue L; Peeters M; Van Damme N
Oncol Rep; 2009 Jul; 22(1):105-13. PubMed ID: 19513511
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
